• FDA confirms positive review of Syntara's clinical development plan and phase 2b trial protocol
• Syntara proposes to undertake a material capital raising
• Trading halt to remain in place until announcement of proposed capital raising

Syntara Limited (ASX: SNT) has requested a continuation of the trading halt requested on 27 April 2026, pending an announcement in relation to correspondence from the U.S. Food and Drug Administration (FDA). The company has received confirmation from the FDA of a positive review of its proposed clinical development plan and phase 2b clinical trial protocol. In light of this, Syntara is now proposing to undertake a material capital raising. The company has requested the trading halt remain in place until the earlier of commencement of trading on Wednesday, 29 April 2026 and the time at which Syntara makes an announcement to the market regarding the proposed capital raising. Syntara confirms it is not aware of any reason why the continuation of the trading halt should not be granted or of any other information necessary to inform the market about the trading halt. The ASX has agreed to the continuation of the trading halt as requested.